- Home
- PRLD vs INCR Comparison
PRLD vs INCR Comparison
Compare PRLD & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | INCR |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 79.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRLD | INCR |
|---|---|---|
| Price | $2.78 | $0.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 534.1K | 190.7K |
| Earning Date | 11-12-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,500,000.00 | ★ $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.00 | N/A |
| 52 Week Low | $0.61 | $0.68 |
| 52 Week High | $4.22 | $1.78 |
Technical Indicators
Market Signals| Indicator | PRLD | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.95 | 31.27 |
| Support Level | $2.37 | $0.87 |
| Resistance Level | $3.00 | $1.08 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 78.39 | 33.32 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.